July 22nd (Wed.) 19:30 - 21:00 Entrepreneur Pitch 1
Name /JelloX Biotech Inc.
Address /Rm. 718, Center of Innovative Incubator, NTHU., No.101, Sec. 2, KuangFu Rd., East Dist., Hsinchu City 300044, Taiwan
Name /Jarvis Lin
Telephone /(Work) +886-3-5620829
JelloX Biotech Inc. is a next generation pathology company that revolutionizes the way to image tissue biopsy with an extra dimension. JelloX 3D imaging technology not only scans clinical tissue samples as a whole but also preserves tissue structural integrity to cellular level, providing hundreds times more data and comprehensive profile of valuable biopsy than conventional 2D pathology diagnosis. Key breakthrough proprietary technologies include high accuracy imaging, high speed 3D digital imaging scanner, and unique AI analysis software with cloud server in support of quantitative characterization of clinical tissue biopsy as well as precision diagnosis by physicians in 7 medical centers in Taiwan.
Our JX ACE 3D pathological imaging and analysis service focuses on providing 3D pathology imaging and analysis for various solid tumors such as breast, lung, head and neck cancer. The JX ACE service captures 3D morphology of tumor specimen and 3D expression profile of clinical biomarkers including PD-L1, TTF1, Her2, and CD-series IVD grade antibodies.
After 3D imaging process, customers would receive the data through cloud server and analyze the data according to their needs. Along with the world first deep learning AI-assisted software, tumor recognition, antibody quantification, and feature extracting functions have been accomplished in service platform.
JX ACE service featured with: (1) hundreds times information, (2) Rapid process, and (3) AI-assist analysis to achieve comprehensive understanding of microenvironment and heterogeneity of tumor.
JelloX is now building an auxiliary diagnostic system with a database of more than 100 TB 3D images to facilitate high end physical examination and assist patient screening in clinical trials; our ultimate goal is to enhance probability-of-success of new cancer drug development for global biotech companies and pharmaceutical companies. The final goals are developing high quality innovative products with FDA/TFDA certificates to benefit patients and establishing new industry standard of 3D pathology for precision cancer diagnosis.
Name /Jarvis Lin